May 2, 2023 | Blog, Shareholder Investigations
Investors of Icahn Enterprises Stock Who Have Suffered Losses of $100,000 or More Encouraged to Contact Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Icahn Enterprises L.P. (“Icahn Enterprises”) (NASDAQ: IEP).
INVESTORS OF ICAHN ENTERPRISES STOCK WHO HAVE SUFFERED FINANCIAL LOSSES OF $100,000 OR MORE ARE ENCOURAGED TO CLICK HERE TO CONTACT KEHOE LAW FIRM, P.C. AND PROVIDE DETAILS OF THEIR ICAHN ENTERPRISES SECURITIES.
Investors should be aware that Yahoo! Finance published a news report by The Telegraph that “Carl Icahn, one of Wall Street’s best-known activist investors, has become the target of a short-seller which has accused the billionaire of inflating the value of his empire.”
The Telegraph also reported that “Hindenburg Research accused the hedge fund manager of operating a ‘[P]onzi-like economic structure’ through his $15bn fund, Icahn Enterprises, and claimed its value had been inflated by at least 75pc.”
Shares of Icahn Enterprises stock were down more than 25% during intraday trading on May 2, 2023.
SHAREHOLDERS OF ICAHN ENTERPRISES WHO SUFFERED LOSSES OF $100,000 OR MORE ARE ALSO ENCOURAGED TO CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], TO LEARN MORE ABOUT THE INVESTIGATION OR POTENTIAL LEGAL CLAIMS.
Apr 7, 2023 | Blog, Shareholder Investigations
Investors of Ascendis Pharma A/S Stock Who Have Suffered Losses of At Least $50,000 Encouraged to Contact Kehoe Law Firm, P.C. – ASND
Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Ascendis Pharma A/S (“Ascendis,” “Ascendis Pharma” or the “Company”) (NASDAQ: ASND).
INVESTORS OF ASCENDIS PHARMA STOCK WHO HAVE SUFFERED FINANCIAL LOSSES OF $50,000 OR MORE ARE ENCOURAGED TO CLICK HERE TO CONTACT KEHOE LAW FIRM, P.C. AND PROVIDE DETAILS OF THEIR ASCENDIS SECURITIES.
Investors should be aware that on April 3, 2023, Ascendis “. . . announced that the U.S. Food & Drug Administration (‘FDA’) has notified the Company that, as part of their ongoing review, the FDA has identified deficiencies in the Company’s New Drug Application (‘NDA’) for TransCon PTH (palopegteriparatide) in hypoparathyroidism that at this time precludes them from holding further discussions about labeling and post-marketing requirements/commitments. The deficiencies were not disclosed in the letter.”
ASCENDIS PHARMA SHAREHOLDERS WHO SUFFERED SIGNIFICANT LOSSES ARE ALSO ENCOURAGED TO CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], TO LEARN MORE ABOUT THE INVESTIGATION OR POTENTIAL LEGAL CLAIMS.
Mar 23, 2023 | Blog, Shareholder Investigations
Investors of Coinbase Stock With At Least $250,000 in Losses Encouraged to Contact Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Coinbase Global Inc. (“Coinbase” or the “Company”) (NASDAQ: COIN).
INVESTORS OF COINBASE STOCK WHO HAVE SUFFERED LOSSES OF $250,000 OR MORE ARE ENCOURAGED TO CLICK HERE TO CONTACT KEHOE LAW FIRM, P.C. AND PROVIDE DETAILS OF THEIR COINBASE SECURITIES.
Coinbase recently reported that “[o]n March 22, 2023, Coinbase . . . received a ‘Wells Notice’ from the Staff . . . of the Securities and Exchange Commission . . . stating that the Staff has advised the Company that it made a ‘preliminary determination’ to recommend that the SEC file an enforcement action against the Company alleging violations of the federal securities laws, including the Securities Exchange Act of 1934, as amended (the ‘Exchange Act’), and the Securities Act of 1933, as amended (the ‘Securities Act’).”
Further, Coinbase reported that “[b]ased on discussions with the Staff, the Company believes these potential enforcement actions would relate to aspects of the Company’s spot market, staking service Coinbase Earn, Coinbase Prime and Coinbase Wallet. The potential civil action may seek injunctive relief, disgorgement, and civil penalties.”
On this news, Coinbase stock was down more than 17% during intraday trading on March 23, 2023.
COINBASE SHAREHOLDERS WHO HAVE SUFFERED FINANCIAL LOSSES OF AT LEAST $250,000 ARE ALSO ENCOURAGED TO CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], TO LEARN MORE ABOUT THE INVESTIGATION OR POTENTIAL LEGAL CLAIMS.
Mar 13, 2023 | Blog, Shareholder Investigations
BigBear.ai Investors Who Held GigCapital4 Stock Encouraged to Contact Kehoe Law Firm, P.C. – Breach of Fiduciary Duties Investigation
Kehoe Law Firm, P.C. is investigating whether certain directors and officers of GigCapital4, Inc. (“GigCapital4), now known as BigBear.ai Holdings, Inc. (“BigBear”) (NYSE: BBAI), breached their fiduciary duties to GigCapital4 and its shareholders.
On December 7, 2021, BigBear announced the completion of the “business combination” with Special Purpose Acquisition Company (“SPAC”) GigCapital4, which was approved on December 3, 2021 at a Special Meeting of GigCapital4’s stockholders.
The investigation primarily concerns whether GigCapital4 breached its fiduciary duties to GigCapital4 and its shareholders by not providing relevant information to GigCapital4 shareholders prior to the merger.
INVESTORS OF BIGBEAR STOCK WHO HELD GIGCAPITAL4 SHARES ARE ENCOURAGED TO CLICK HERE TO CONTACT KEHOE LAW FIRM, P.C. AND PROVIDE DETAILS OF THEIR BIGBEAR/GIGCAPITAL4 SECURITIES.
BIGBEAR SHAREHOLDERS WHO HELD GIGCAPITAL4 STOCK ARE ALSO ENCOURAGED TO CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], TO LEARN MORE ABOUT THE INVESTIGATION OR POTENTIAL LEGAL CLAIMS.
Feb 24, 2023 | Blog, Shareholder Investigations
Investors of Nektar Therapeutics Stock Since At Least June 2022 Encouraged to Contact Kehoe Law Firm, P.C. – Breach of Fiduciary Duties Investigation
Kehoe Law Firm, P.C. is investigating whether certain directors and officers of Nektar Therapeutics (“Nektar” or “Nektar Therapeutics”) (NASDAQ: NKTR) breached their fiduciary duties to Nektar and its shareholders.
The investigation concerns whether members of Nektar’s board of directors or senior management failed to manage Nektar Therapeutics in an acceptable manner, in breach of their fiduciary duties to Nektar, and whether Nektar Therapeutics and its shareholders have suffered damages as a result.
INVESTORS OF NEKTAR THERAPEUTICS WHO HAVE HELD THEIR NKTR STOCK SINCE AT LEAST JUNE 2022 ARE ENCOURAGED TO CLICK HERE TO CONTACT KEHOE LAW FIRM, P.C. AND PROVIDE DETAILS OF THEIR NKTR SECURITIES.
SHAREHOLDERS OF NEKTAR THERAPEUTICS WHO HAVE HELD THEIR STOCK SINCE AT LEAST JUNE 2022 ARE ALSO ENCOURAGED TO CONTACT JOHN KEHOE, ESQ., (215) 792-6676, EXT. 801, [email protected], [email protected], TO LEARN MORE ABOUT THE INVESTIGATION OR POTENTIAL LEGAL CLAIMS.
